Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models   new Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources

GENE - CHEMICAL INTERACTIONS REPORT

RGD ID: 2901
Species: Rattus norvegicus
RGD Object: Gene
Symbol: Il6
Name: interleukin 6
Acc ID: CHEBI:4031
Term: cyclosporin A
Definition: A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle.
Chemical ID: MESH:D016572
Note: Use of the qualifier "multiple interactions" designates that the annotated interaction is comprised of a complex set of reactions and/or regulatory events, possibly involving additional chemicals and/or gene products.
Object SymbolQualifierEvidenceWithReferenceSourceNotesOriginal Reference(s)
Il6decreases expressionEXP 6480464CTDCyclosporine results in decreased expression of IL6 proteinPMID:25051504
Il6increases expressionEXP 6480464CTDCyclosporine results in increased expression of IL6 proteinPMID:33710703
Il6multiple interactionsEXP 6480464CTDnilotinib inhibits the reaction [Cyclosporine results in increased expression of IL6 protein]PMID:33710703
Il6increases expressionISOIl6 (Mus musculus)6480464CTDCyclosporine results in increased expression of IL6 mRNAPMID:23958496 PMID:27585667
Il6increases expressionISOIL6 (Homo sapiens)6480464CTDCyclosporine results in increased expression of IL6 mRNAPMID:20106945
Il6multiple interactionsISOIl6 (Mus musculus)6480464CTDCyclosporine affects the reaction [sodium arsenite affects the expression of IL6 mRNA]; Cyclosporine inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of IL6 protein]; ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate inhibits the reaction [Cyclosporine results in increased expression of IL6 mRNA]; parthenolide inhibits the reaction [Cyclosporine results in increased expression of IL6 mRNA]; sulforaphane inhibits the reaction [Cyclosporine results in increased expression of IL6 mRNA]; TLR4 gene mutant form inhibits the reaction [Cyclosporine results in increased expression of IL6 mRNA]PMID:21381053 PMID:23958496 PMID:27585667 PMID:36557995
Il6multiple interactionsISOIL6 (Homo sapiens)6480464CTD[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of IL6 mRNAPMID:33819548
Go Back to source page   Continue to Ontology report